• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » MDS Cuts 210 Staff in North America

MDS Cuts 210 Staff in North America

July 18, 2008
CenterWatch Staff

MDS has become the second pharmaceutical services company in as many weeks to report a round of layoffs. Toronto-based MDS has slashed 210 jobs from its North American workforce, representing 4% of MDS’s 5,500 worldwide employees. The company stated that 75% of the lay offs will come from its MDS Pharma Services (contract research) division with the remainder from its Analytical Technologies (medical equipment manufacturing) group. MDS cited that the action will result in third quarter charges of $18 million and $10 million in write downs at its Pharma Services laboratory based in Montreal. Company shares rose 1.8 per cent, or 26 cents, to $14.85 in trading on the Toronto Stock Exchange.  MDS is scheduled to release its third quarter fiscal 2008 earnings on September 4, 2008.

MDS Pharma Services, based in King of Prussia, Pa., recently opened a new office in downtown Tokyo to support operations across the region. MDS Pharma’s new office will act as another extension to the company’s network hubs in Singapore and Australia (central labs), Taiwan (preclinical) and Beijing, Malaysia and Australia (late stage clinical work).MDS Pharma already has one office in Tokyo; however, it offers only development and regulatory services and central lab work. MDS Pharma also recently launched its newest version of ClinQuick, the company’s proprietary phase I trial management platform. The system, built in-house, has been in use since 1993 and was utilized in more than 3,000 early phase studies. The new enhanced software platform includes a more user-friendly interface, improved navigation and faster, more flexible reporting capabilities. The software will eventually allow the company’s sponsor clients to access and manage clinical data via the web.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing